Daphne A. Stanley
A5091488074- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Hepatitis B Virus Studies
- Virus-based gene therapy research
- COVID-19 epidemiological studies
- Disaster Response and Management
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Global Security and Public Health
- HIV/AIDS drug development and treatment
- CAR-T cell therapy research
- Plant Virus Research Studies
- T-cell and B-cell Immunology
- HIV Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Poxvirus research and outbreaks
- Toxin Mechanisms and Immunotoxins
- Mosquito-borne diseases and control
- Immunotherapy and Immune Responses
National Institute of Allergy and Infectious Diseases
2011-2024
National Institutes of Health
2010-2024
Institut de Recherche Vaccinale
2015
Sensei Biotherapeutics (United States)
2009
Antibodies block Ebola virus entry The recent outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of 1995 Kikwit demonstrated their therapeutic efficacy virus–infected macaques. In fact, one antibody protected macaques when it was given up 5 days after infection. Misasi solved crystal structures fragments bound glycoprotein (GP), which mediates viral cell entry....
The worst Ebola virus disease (EVD) outbreak in history has resulted more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials an attenuated, replication-competent, recombinant vesicular stomatitis (rVSV)-based vaccine candidate designed to prevent EVD.
The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. development an effective vaccine is a priority for control future outbreak.
The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international response to accelerate the availability a preventive vaccine. A replication-defective recombinant chimpanzee adenovirus type 3–vectored ebolavirus vaccine (cAd3-EBO), encoding glycoprotein from Zaire and Sudan species, that offers protection in nonhuman primate model, was rapidly advanced into phase 1 clinical evaluation.
The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing glycoprotein (ChAd3-EBO-Z). We aimed investigate the safety, tolerability, and immunogenicity ChAd3-EBO-Z in Malian US adults, assess effect boosting Malians with modified vaccinia Ankara other filovirus antigens (MVA-BN-Filo).
The use of adenoviruses (Ad) as vaccine vectors against a variety pathogens has demonstrated their capacity to elicit strong antibody and cell-mediated immune responses. Adenovirus serotype C vectors, such Ad 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely after single inoculation at dose 10(10) viral particles. However, the clinical application based on Ad5 may be hampered, since impairment efficacy been for humans nonhuman primates with high levels preexisting...
A major challenge in developing vaccines for emerging pathogens is their continued evolution and ability to escape human immunity. Therefore, an important goal of vaccine research advance candidates with sufficient breadth respond new outbreaks previously undetected viruses. Ebolavirus (EBOV) have demonstrated protection against EBOV infection nonhuman primates (NHP) show promise clinical trials but immune occurs only whose antigens are matched the infectious species. 2007 hemorrhagic fever...
Ebola virus disease (EVD) is a filoviral infection caused by species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan (SUDV). We investigated safety immunogenicity heterologous prime-boost regimen involving chimpanzee adenovirus 3 vectored vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed recombinant modified vaccinia Ankara EBOV (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials healthy adults United States (US) Uganda...
Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality rates humans of up to 90%. MARV has been identified as category A bioterrorism agent by the Centers for Disease Control and Prevention (CDC) priority pathogen National Institute Allergy Infectious Diseases (NIAID), needing urgent research development countermeasures because high public health risk it poses. The recent cases West Africa underscore substantial outbreak potential this virus. cross-border...
We recently identified a single potently neutralizing monoclonal antibody (mAb), mAb114, isolated from human survivor of natural Zaire ebolavirus (EBOV) infection, which fully protects nonhuman primates (NHPs) against lethal EBOV challenge. To evaluate the ability vaccination to generate mAbs such as we cloned antibodies NHPs vaccinated with vectors encoding glycoprotein (GP). 14 unique potent binding GP, 4 were neutralized and had functional characteristics mAb114. These vaccine-induced...
Abstract Marburg virus (MARV) causes a severe hemorrhagic fever disease in primates with mortality rates humans up to 90%. Since 2018, MARV has been identified as priority pathogen by the WHO, needing urgent research and development of countermeasures due high public health risk it poses. Recently, first case West Africa underscored significant outbreak potential this virus. The for cross border spread had occurred during Ebola 2014-2016 illustrates critical need vaccines. To support...
Abstract Infection with Sudan virus (SUDV) is characterized by an aggressive disease course case fatality rates between 40-100% and no approved vaccines or therapeutics. SUDV causes sporadic outbreaks in sub-Saharan Africa, including a recent outbreak Uganda which has resulted over 100 confirmed cases one month. Prior vaccine therapeutic efforts have historically prioritized Ebola (EBOV), leading to significant gap available treatments. Two vaccines, Erbevo ® Zabdeno /Mvabea , are licensed...
Heterologous prime-boost immunization regimens are a common strategy for many vaccines. DNA prime rAd5-GP boost has been demonstrated to protect non-human primates against lethal challenge of Ebola virus, pathogen that causes fatal hemorrhagic disease in humans. This protection correlates with antibody responses and is also associated IFNγ + TNFα double positive CD8 T-cells. In this study, we compared single vs. multiple immunizations, short long time intervals between the rAd5 evaluate...
Fusion inhibitors are a relatively new class of antiretroviral drugs that block conformational changes in the HIV envelope glycoprotein (Env) critical for virus-cell fusion. Proof-of-concept this therapeutic approach is provided by enfuvirtide, peptide inhibits terminal gp41. The identification non-peptide, orally bioavailable fusion may provide valuable options people living with HIV/AIDS. Using cell-based assay inhibition Env we identified three structurally distinct series drug-like small...